Amend Surgical entered into a funding agreement with The Florida Institute for the Commercialization of Public Research addressing newly-licensed technology developed at the University of Florida.
Amend Surgical received its first FDA 510(k) clearance in 1Q17 for NanoFUSE® BA as a bone graft extender for spine and orthopaedic applications. Its pipeline includes osteoinductive bone extracts and future disruptive products based on therapeutic additives, like antibiotics and natural bone morphogenic proteins.
The Florida Institute bridges early funding gaps for companies that license technology out of Florida-based universities and research institutions. Earlier this year, Amend entered into an exclusive agreement with The University of Florida Research Foundation to license patents for the development of Biomimetic Bone artificial bone substitute.
Sources: Florida Institute for the Commercialization of Public Research; ORTHOWORLD Inc.
Amend Surgical entered into a funding agreement with The Florida Institute for the Commercialization of Public Research addressing newly-licensed technology developed at the University of Florida.
Amend Surgical received its first FDA 510(k) clearance in 1Q17 for NanoFUSE® BA as a bone graft extender for spine and orthopaedic applications....
Amend Surgical entered into a funding agreement with The Florida Institute for the Commercialization of Public Research addressing newly-licensed technology developed at the University of Florida.
Amend Surgical received its first FDA 510(k) clearance in 1Q17 for NanoFUSE® BA as a bone graft extender for spine and orthopaedic applications. Its pipeline includes osteoinductive bone extracts and future disruptive products based on therapeutic additives, like antibiotics and natural bone morphogenic proteins.
The Florida Institute bridges early funding gaps for companies that license technology out of Florida-based universities and research institutions. Earlier this year, Amend entered into an exclusive agreement with The University of Florida Research Foundation to license patents for the development of Biomimetic Bone artificial bone substitute.
Sources: Florida Institute for the Commercialization of Public Research; ORTHOWORLD Inc.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.